Karaca, B. Et Al. 2015. Docetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell lines. Cancer Chemotherapy and Pharmacology , vol.75, no.6 , 1273-1280.

Karaca, B., Degirmenci, M., Ozveren, A., ATMACA İLHAN, H., Bozkurt, E., Karabulut, B., ... Sanli, U. A.(2015). Docetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell lines. Cancer Chemotherapy and Pharmacology , vol.75, no.6, 1273-1280.

Karaca, Burcak Et Al. "Docetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell lines," Cancer Chemotherapy and Pharmacology , vol.75, no.6, 1273-1280, 2015

Karaca, Burcak Et Al. "Docetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell lines." Cancer Chemotherapy and Pharmacology , vol.75, no.6, pp.1273-1280, 2015

Karaca, B. Et Al. (2015) . "Docetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell lines." Cancer Chemotherapy and Pharmacology , vol.75, no.6, pp.1273-1280.

@article{article, author={Burcak Karaca Et Al. }, title={Docetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell lines}, journal={Cancer Chemotherapy and Pharmacology}, year=2015, pages={1273-1280} }